Back to results
US 12,516,348 B2Granted
Recombinant nucleic acid construct
AssigneePANTHERNA THERAPEUTICS GmbH
InventorsKlaus Giese, Oliver Keil, Jörg Kaufmann
Life of this patent
Estimating the term…
Abstract
The present invention is related to a recombinant nucleic acid construct comprising in 5′→3′ direction a 5′ UTR, a coding region coding for an effector molecule, and a 3′ UTR, wherein 5′ UTR is selected from the group comprising a 5′ UTR of a gene or a derivative thereof having a nucleotide identity of at least 85%, wherein the gene is selected from the group consisting of MCP-1, RPL12s.c., Ang-2, HSP70, H3.3., Galectin-9, GADD34, EDN1, HSP70m5, E-selectin, ICAM-1, IL-6 and vWF.
Claims17
A recombinant nucleic acid construct comprising in 5′→3′ direction
- a 5′ UTR,
- a coding region coding for an effector molecule, and
- a 3′ UTR,
- wherein the 5′ UTR is a 5′ UTR of a gene coding for MCP-1,
- wherein the 3′ UTR is a 3′ UTR of a gene coding for vWF,
- wherein the effector molecule is effective in restoring a cellular function of a cell or is effective in exercising a therapeutic effect in or on a cell, and
- wherein the recombinant nucleic acid construct is different from a wild type mRNA coding for the effector molecule.
4 more elements
Dependencies are inferred from the claim text.